S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Defy EOY Volatility with Artificial Intelligence (Ad)pixel
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:ALIM

Alimera Sciences - ALIM Stock Forecast, Price & News

$3.58
+0.13 (+3.77%)
(As of 12/2/2022 08:59 PM ET)
Add
Compare
Today's Range
$3.42
$3.60
50-Day Range
$3.44
$6.16
52-Week Range
$3.36
$7.92
Volume
10,500 shs
Average Volume
22,448 shs
Market Capitalization
$25.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

Alimera Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
88.5% Upside
$6.75 Price Target
Short Interest
Healthy
0.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Alimera Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.33) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

734th out of 1,033 stocks

Pharmaceutical Preparations Industry

356th out of 502 stocks

ALIM stock logo

About Alimera Sciences (NASDAQ:ALIM) Stock

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Stock News Headlines

7 Stocks That Could Implode at Any Moment
Alimera Sciences Q3 2022 Earnings Preview
10 Best Low Price Pharma Stocks To Buy Now
Alimera Sciences Inc ALIM Stock News
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Company Calendar

Last Earnings
10/27/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALIM
Employees
145
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+88.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-4,370,000.00
Pretax Margin
-34.10%

Debt

Sales & Book Value

Annual Sales
$59.03 million
Book Value
($5.33) per share

Miscellaneous

Free Float
6,094,000
Market Cap
$25.05 million
Optionable
Optionable
Beta
1.26

Social Links


Key Executives

  • Mr. Charles Daniel Myers (Age 68)
    Non-Exec. Chairman & Consultant
    Comp: $205k
  • Mr. Richard S. Eiswirth Jr.Mr. Richard S. Eiswirth Jr. (Age 54)
    Pres, CEO & Director
    Comp: $633.87k
  • Mr. David R. Holland (Age 58)
    Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets
    Comp: $448.5k
  • Dr. Philip Ashman Ph.D. (Age 57)
    COO & Sr. VP of Commercial Operations - Europe
    Comp: $462.6k
  • Mr. John Philip JonesMr. John Philip Jones (Age 58)
    Chief Financial Officer
  • Christopher S. Visick
    VP, Gen. Counsel & Sec.
  • Dr. David Dyer M.D.
    Chief Retina Specialist













ALIM Stock - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price forecast for 2023?

2 equities research analysts have issued twelve-month target prices for Alimera Sciences' shares. Their ALIM share price forecasts range from $4.50 to $9.00. On average, they predict the company's share price to reach $6.75 in the next year. This suggests a possible upside of 88.5% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2022?

Alimera Sciences' stock was trading at $5.13 at the beginning of the year. Since then, ALIM shares have decreased by 30.2% and is now trading at $3.58.
View the best growth stocks for 2022 here
.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 23,200 shares, an increase of 12.1% from the October 31st total of 20,700 shares. Based on an average daily volume of 8,800 shares, the short-interest ratio is presently 2.6 days. Approximately 0.4% of the shares of the company are sold short.
View Alimera Sciences' Short Interest
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) posted its quarterly earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.08. The biopharmaceutical company earned $12.15 million during the quarter, compared to analysts' expectations of $12.30 million. During the same quarter in the previous year, the company posted ($0.12) earnings per share.

When did Alimera Sciences' stock split?

Shares of Alimera Sciences reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.61%), Perritt Capital Management Inc. (0.26%) and BlackRock Inc. (0.18%). Insiders that own company stock include James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $3.58.

How much money does Alimera Sciences make?

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $25.06 million and generates $59.03 million in revenue each year. The biopharmaceutical company earns $-4,370,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Alimera Sciences have?

The company employs 145 workers across the globe.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.

This page (NASDAQ:ALIM) was last updated on 12/5/2022 by MarketBeat.com Staff